Clinical and molecular characterization of patients with CLL
| Patient . | Age (y) . | Sex . | Binet stage . | LBC (×10³ cells/μL) . | IGHV status . | IGHV rearrangements . | FISH . | AID . | LPL . | Treatment . | TTFT (mo) . | Clinical disease status . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 60 | F | A | 31.9 | M | VH3-30∗18 | del(11q) | (−) | (−) | No | __ | Indolent |
| 2 | 61 | F | A | 42.62 | M | VH4-34∗01 | Normal | (−) | (−) | No | __ | Indolent |
| 3 | 55 | F | A | 22.90 | M | VH5-51∗01 | N/D | (−) | (−) | No | __ | Indolent |
| 4 | 71 | F | A | 52.42 | M | VH4-30∗02 | Normal | (−) | (+) | No | __ | Indolent |
| 5 | 61 | M | A | 42.7 | M | VH4-59∗01 | del13q/14 | (−) | (−) | No | __ | Indolent |
| 6 | 67 | F | A | 21.6 | M | VH3-33∗01 | del13q/14 | (−) | (−) | No | __ | Indolent |
| 7 | 79 | F | A | 22.52 | M | VH3-48∗03 | del13q/14 | (−) | (−) | No | __ | Indolent |
| 8 | 54 | M | A | 30.06 | M | VH3-7∗01 | Normal | (−) | (−) | No | __ | Indolent |
| 9 | 49 | F | A | 57 | M | VH2-05∗02 | del13q/14 | (−) | (−) | No | __ | Indolent |
| 10 | 76 | M | A | 28.68 | M | VH4-34∗02 | del13q/14 | (−) | (+) | No | __ | Indolent |
| 11 | 71 | M | A | 35.70 | UM | VH1-3∗01 | Tris_12 | (−) | (−) | No | __ | Indolent |
| 12 | 55 | M | A | 14.40 | M | VH3-23∗01 | Normal | (−) | (−) | No | __ | Indolent |
| 13 | 55 | F | A | 16.00 | M | VH4-34∗01 | del13q/14 | (−) | (−) | No | __ | Indolent |
| 14 | 74 | M | A | 16.58 | M | VH1-2∗02 | del13q/14 | (−) | (−) | No | __ | Indolent |
| 15 | 72 | M | A | 22.10 | M | VH2-5∗02 | Normal | (−) | (−) | No | __ | Indolent |
| 16 | 62 | M | C | 170 | UM | VH1-18∗01 | del(11q) | (−) | (+) | Yes | 24 | Progressive |
| 17 | 63 | M | B | 86 | UM | VH3-30∗18 | del13q/14 | (+) | (+) | Yes | 1 | Progressive |
| 18 | 59 | M | C | 67 | UM | VH4-34∗01 | del11q | (−) | (+) | Yes | 1 | Progressive |
| 19 | 52 | M | C | 421 | UM | VH1-69∗01 | Tris_12 | (+) | (+) | Yes | 1 | Progressive |
| 20 | 57 | M | C | 305 | UM | VH1-69∗13 | Tris_12 | (+) | (+) | Yes | 1 | Progressive |
| 21 | 69 | M | C | 6.82 | UM | VH3-21∗01 | Normal | (+) | (+) | Yes | 2 | Progressive |
| 22 | 77 | M | B | 137.78 | M | VH3-23∗01 | N/D | (+) | (−) | Yes | 45 | Progressive |
| 23 | 33 | M | C | 400 | UM | VH4-39 | del13q/14 | (+) | (+) | Yes | 1 | Progressive |
| 24 | 51 | M | C | 120 | UM | VH1-69∗12 | del(11q) | (−) | (+) | Yes | 7 | Progressive |
| 25 | 74 | M | C | 303 | UM | V4-39∗01 | Tris_12 | (−) | (+) | Yes | 1 | Progressive |
| 26 | 63 | F | C | 102.4 | UM | VH4-61∗02 | del(17p) | (+) | (+) | Yes | A/D | Progressive |
| 27 | 50 | M | C | 143.63 | M | VH3-7∗01 | Tris_12 | (+) | (+) | Yes | 3 | Progressive |
| 28 | 69 | M | C | 6 8.16 | UM | VH3-21∗01 | Normal | (+) | (+) | Yes | 2 | Progressive |
| 29 | 45 | M | B | 93.5 | UM | VH1-69∗04 | del13q/14 | (−) | (+) | Yes | 25 | Progressive |
| 30 | 61 | M | C | 215.8 | UM | VH1-69∗13 | del(17p) | (+) | (+) | Yes | 2 | Progressive |
| Patient . | Age (y) . | Sex . | Binet stage . | LBC (×10³ cells/μL) . | IGHV status . | IGHV rearrangements . | FISH . | AID . | LPL . | Treatment . | TTFT (mo) . | Clinical disease status . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 60 | F | A | 31.9 | M | VH3-30∗18 | del(11q) | (−) | (−) | No | __ | Indolent |
| 2 | 61 | F | A | 42.62 | M | VH4-34∗01 | Normal | (−) | (−) | No | __ | Indolent |
| 3 | 55 | F | A | 22.90 | M | VH5-51∗01 | N/D | (−) | (−) | No | __ | Indolent |
| 4 | 71 | F | A | 52.42 | M | VH4-30∗02 | Normal | (−) | (+) | No | __ | Indolent |
| 5 | 61 | M | A | 42.7 | M | VH4-59∗01 | del13q/14 | (−) | (−) | No | __ | Indolent |
| 6 | 67 | F | A | 21.6 | M | VH3-33∗01 | del13q/14 | (−) | (−) | No | __ | Indolent |
| 7 | 79 | F | A | 22.52 | M | VH3-48∗03 | del13q/14 | (−) | (−) | No | __ | Indolent |
| 8 | 54 | M | A | 30.06 | M | VH3-7∗01 | Normal | (−) | (−) | No | __ | Indolent |
| 9 | 49 | F | A | 57 | M | VH2-05∗02 | del13q/14 | (−) | (−) | No | __ | Indolent |
| 10 | 76 | M | A | 28.68 | M | VH4-34∗02 | del13q/14 | (−) | (+) | No | __ | Indolent |
| 11 | 71 | M | A | 35.70 | UM | VH1-3∗01 | Tris_12 | (−) | (−) | No | __ | Indolent |
| 12 | 55 | M | A | 14.40 | M | VH3-23∗01 | Normal | (−) | (−) | No | __ | Indolent |
| 13 | 55 | F | A | 16.00 | M | VH4-34∗01 | del13q/14 | (−) | (−) | No | __ | Indolent |
| 14 | 74 | M | A | 16.58 | M | VH1-2∗02 | del13q/14 | (−) | (−) | No | __ | Indolent |
| 15 | 72 | M | A | 22.10 | M | VH2-5∗02 | Normal | (−) | (−) | No | __ | Indolent |
| 16 | 62 | M | C | 170 | UM | VH1-18∗01 | del(11q) | (−) | (+) | Yes | 24 | Progressive |
| 17 | 63 | M | B | 86 | UM | VH3-30∗18 | del13q/14 | (+) | (+) | Yes | 1 | Progressive |
| 18 | 59 | M | C | 67 | UM | VH4-34∗01 | del11q | (−) | (+) | Yes | 1 | Progressive |
| 19 | 52 | M | C | 421 | UM | VH1-69∗01 | Tris_12 | (+) | (+) | Yes | 1 | Progressive |
| 20 | 57 | M | C | 305 | UM | VH1-69∗13 | Tris_12 | (+) | (+) | Yes | 1 | Progressive |
| 21 | 69 | M | C | 6.82 | UM | VH3-21∗01 | Normal | (+) | (+) | Yes | 2 | Progressive |
| 22 | 77 | M | B | 137.78 | M | VH3-23∗01 | N/D | (+) | (−) | Yes | 45 | Progressive |
| 23 | 33 | M | C | 400 | UM | VH4-39 | del13q/14 | (+) | (+) | Yes | 1 | Progressive |
| 24 | 51 | M | C | 120 | UM | VH1-69∗12 | del(11q) | (−) | (+) | Yes | 7 | Progressive |
| 25 | 74 | M | C | 303 | UM | V4-39∗01 | Tris_12 | (−) | (+) | Yes | 1 | Progressive |
| 26 | 63 | F | C | 102.4 | UM | VH4-61∗02 | del(17p) | (+) | (+) | Yes | A/D | Progressive |
| 27 | 50 | M | C | 143.63 | M | VH3-7∗01 | Tris_12 | (+) | (+) | Yes | 3 | Progressive |
| 28 | 69 | M | C | 6 8.16 | UM | VH3-21∗01 | Normal | (+) | (+) | Yes | 2 | Progressive |
| 29 | 45 | M | B | 93.5 | UM | VH1-69∗04 | del13q/14 | (−) | (+) | Yes | 25 | Progressive |
| 30 | 61 | M | C | 215.8 | UM | VH1-69∗13 | del(17p) | (+) | (+) | Yes | 2 | Progressive |
AID and LPL have previously been proposed as prognosis markers in CLL (Heintel et al25 and Oppezzo et al,26 respectively).
A/D, CLL-associated death; AID, activation-induced cytidine deaminase; FISH, fluorescence in situ hybridization; F, female; LBC, lymphocyte blood count; LPL, lipoprotein lipase; M, male; N/D, No data; TTFT, time to first treatment.